glp 1 agonist black box warning The Dark Side of Ozempic Doctors warn GLP-1 users about

Description

In 2005, a new treatment of T2DM based on the action of GLP-1 was introduced (137)

By activating GLP-1 receptors, it stimulates insulin secretion from pancreatic beta cells, leading to better glucose utilization and reduced blood sugar levels

Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K

In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease

The medical director of the VCU Health Medical Weight Loss Program explains what these medications do to the body and why they might not be suited for everyone